Tag: BIOAGE

How did the year 2025 turn out for longevity biotech? Was it surprising or more of the same? Exciting or disappointing? Was the progress fast-moving or excruciatingly slow? What should we expect in 2026? We asked five leading experts to weigh in. Where did longevity biotech exceed your expectations in 2025, and where did it...

RICHMOND, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company has made the decision to discontinue the ongoing STRIDES Phase 2 study of its investigational drug candidate...

BioAge Labs, Inc., (“BioAge”), a clinical-stage biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today announced plans to initiate a Phase 2 trial of its oral apelin receptor agonist BGE-105 (azelaprag) co-administered with the GLP-1/GIP receptor agonist tirzepatide for treatment of obesity. BioAge plans to initiate the...

BioAge Labs has concluded a Phase 1b study in which human volunteers undergoing 10 days of bed rest were shown to have their related muscle atrophy significantly attenuated by BGE-105. RICHMOND, Calif.--(BUSINESS WIRE)--BioAge Labs, Inc. (“BioAge”), a clinical-stage biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today...

BioAge, a biotechnology company that intends to target aging on the molecular level, has completed a Phase 1b clinical trial of BGE-105, a small molecule that influences muscular metabolism. Below is the company's full press release. RICHMOND, Calif.--(BUSINESS WIRE)-- BioAge Labs, Inc., a biotechnology company developing therapeutics that target the molecular causes of aging to...

A research paper that has just been peer reviewed and published in Nature has described how disrupting an immune pathway that is upregulated in aging decreases the lethality of COVID-19 in a mouse model. Mice with COVID-19 As the researchers explain, normal mice do not use the same angiotensin converting enzyme 2 (ACE2) as humans,...